Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targeting mucosal inflammation

Biogen Idec Inc. has long been interested in the late stages of inflammation where tissue remodeling and fibrosis occur. Last week's deal with LigoCyte Pharmaceuticals Inc. adds another piece to the puzzle with a preclinical program targeting the CD103 integrin to treat chronic inflammatory diseases.

Integrins

Read the full 454 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE